Long-Term Study Shows Sustained Remission With Eli Lilly’s Ulcerative Colitis Drug

All NewsOctober 7, 2025

Eli Lilly’s four-year LUCENT-3 study shows Omvoh maintained high remission rates and a consistent safety profile in ulcerative colitis patients.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent